Cargando…

Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

INTRODUCTION: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. METHODS: We reviewe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasiri, Mohammad Javad, Zangiabadian, Moein, Arabpour, Erfan, Amini, Sirus, Khalili, Farima, Centis, Rosella, D'Ambrosio, Lia, Denholm, Justin T., Schaaf, H. Simon, van den Boom, Martin, Kurhasani, Xhevat, Dalcolmo, Margareth Pretti, Al-Abri, Seif, Chakaya, Jeremiah, Alffenaar, Jan-Willem, Akkerman, Onno, Silva, Denise Rossato, Muňoz-Torrico, Marcela, Seaworth, Barbara, Pontali, Emanuele, Saderi, Laura, Tiberi, Simon, Zumla, Alimuddin, Migliori, Giovanni Battista, Sotgiu, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731904/ https://www.ncbi.nlm.nih.gov/pubmed/35245659 http://dx.doi.org/10.1016/j.ijid.2022.02.043

Ejemplares similares

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Migliori, Giovanni Battista, et al.
Publicado: (2017)

Delamanid expanded access novel treatment of drug resistant tuberculosis
por: Rustomjee, Roxana, et al.
Publicado: (2015)

First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline
por: Tadolini, Marina, et al.
Publicado: (2016)

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis
por: Silva, Denise Rossato, et al.
Publicado: (2018)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

Tuberculosis in the time of COVID-19: quality of life and digital innovation
por: Visca, Dina, et al.
Publicado: (2020)

Tuberculosis series
por: Silva, Denise Rossato, et al.
Publicado: (2018)

Pulmonary tuberculosis in intensive care setting, with a focus on the use of severity scores, a multinational collaborative systematic review
por: Galvin, J., et al.
Publicado: (2022)

Recent developments in the diagnosis and management of tuberculosis
por: Sulis, Giorgia, et al.
Publicado: (2016)

Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence
por: Migliori, Giovanni Battista, et al.
Publicado: (2021)

World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic
por: Petersen, Eskild, et al.
Publicado: (2022)

Breathing Back Better! A State of the Art on the Benefits of Functional Evaluation and Rehabilitation of Post-Tuberculosis and Post-COVID Lungs
por: Pontali, Emanuele, et al.
Publicado: (2022)

Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study
por: Migliori, Giovanni Battista, et al.
Publicado: (2022)

Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network
por: D’Ambrosio, Lia, et al.
Publicado: (2021)

Global TB Network: working together to eliminate tuberculosis
por: Silva, Denise Rossato, et al.
Publicado: (2018)

The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB
por: Chakaya, Jeremiah, et al.
Publicado: (2022)

Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe?
por: Silva, Denise Rossato, et al.
Publicado: (2021)

Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation
por: Tiberi, Simon, et al.
Publicado: (2019)

Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: A case report and review of the literature
por: Esposito, Susanna, et al.
Publicado: (2016)

Tuberculosis Incidence and Case Notification Rates in Kosovo and the Balkans in 2012: Cross-country Comparison
por: Kurhasani, Xhevat, et al.
Publicado: (2014)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives
por: Pontali, Emanuele, et al.
Publicado: (2019)

Amikacin liposome and Mycobacterium avium complex: A systematic review
por: Zangiabadian, Moein, et al.
Publicado: (2022)

The role of delamanid in the treatment of drug-resistant tuberculosis
por: Lewis, Joseph M, et al.
Publicado: (2015)

Profile of delamanid for the treatment of multidrug-resistant tuberculosis
por: Szumowski, John D, et al.
Publicado: (2015)

Reply to Chang and Yew
por: Sotgiu, Giovanni, et al.
Publicado: (2020)

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
por: Tanneau, Lénaïg, et al.
Publicado: (2022)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!
por: Tiberi, Simon, et al.
Publicado: (2018)

New anti-tuberculosis drugs and regimens: 2015 update
por: D'Ambrosio, Lia, et al.
Publicado: (2015)

Tuberculosis elimination: where are we now?
por: Matteelli, Alberto, et al.
Publicado: (2018)

Delamanid: A new armor in combating drug-resistant tuberculosis
por: Xavier, Alphienes Stanley, et al.
Publicado: (2014)

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
por: Skripconoka, Vija, et al.
Publicado: (2013)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
por: Hu, Minhui, et al.
Publicado: (2016)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Early experience of delamanid in extensively drug-resistant pulmonary tuberculosis
por: Marwah, Vikas, et al.
Publicado: (2023)

Bacille Calmette-Guérin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection — Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base
por: Nachega, Jean B., et al.
Publicado: (2021)

Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review
por: Sotgiu, Giovanni, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o1k19898c1n52fif819fua5893